DPC A80350
Alternative Names: DPC-A80350Latest Information Update: 15 Jan 2008
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 14 Mar 2001 New profile
- 14 Mar 2001 Preclinical development for Solid tumours in USA (Unknown route)